Leading Air Cargo Services Provider Purchases Implant Sciences' QS-B220 Explosives Trace Detectors

WILMINGTON, Mass., Nov. 27, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it has sold its QS-B220 desktop explosives trace detectors to a leading air cargo services provider, which provides TSA Certified Cargo Screening. 

"The air cargo services providers are looking for new technologies to improve their operational capabilities and reduce operating costs," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "They view the QS-B220 as an integral component of this strategy, citing low cost of ownership, automatic calibration, ease of use and remote diagnostic capabilities. The value proposition offered by Implant Sciences is far superior to competing explosives trace technologies, coupled with highly customer focused aftermarket support are critical attributes to the decision makers."

"Our technology, which truly is the new standard in trace detection, continues to be recognized by freight forwarders for its operational and cost advantages," commented Implant Sciences' Chief Executive Officer, Glenn D. Bolduc. "The needs of air cargo screening facilities were one of our prime considerations when we built the QS-B220. It's exciting to see our ideas validated by an industry leader."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than competing products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. The Company is the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. In addition to being named a Qualified Product by TSA on the Air Cargo Screening Technology List, the QS-B220 has received certification from STAC in France, and Designation as a Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). Implant Sciences' QS-H150 handheld explosives trace detector is also a Designated Qualified Anti-Terrorism Technology under the SAFETY Act. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700       

or

Investor Contact:
Laurel Moody
646-810-0608

SOURCE Implant Sciences